- Trial phase
- Phase 3
- Time to market
- Unknown; the sole remaining Phase 3 trial (LILAC-TIMI 76) is still recruiting with estimated completion in December 2027, meaning any potential regulatory filing is likely 3+ years away at best.
- Why 3/10
- No hard dated catalyst is scheduled within the next ~12 months: the two cancer Phase 3 trials were terminated in early 2026 (past events), and the remaining LILAC-TIMI 76 Phase 3 trial is still recruiting with estimated primary completion in December 2027. For a mega-cap diversified pharma like Novartis, this single drug represents a small fraction of enterprise value, capping the impact score.
The next catalyst is the LILAC-TIMI 76 Phase 3 readout (abelacimab vs placebo in AF patients unsuitable for oral anticoagulation), but with estimated completion in December 2027, no near-term binary is on the calendar. For a mega-cap like Novartis, abelacimab is a small pipeline component; the cancer-trial failures are already priced in. Watch for any interim LILAC analysis or regulatory guidance, but the next hard catalyst is likely 12+ months away.
Price Chart
Executive Summary
Abelacimab is a once-monthly injectable monoclonal antibody that blocks Factor XI, being developed by Novartis (NVS) as a potentially safer anticoagulant. It showed impressive bleeding reduction (67% vs rivaroxaban) in the Phase 2 AZALEA-TIMI 71 trial. However, in 2026 Novartis terminated two Phase 3 cancer-associated thrombosis trials after abelacimab failed to beat Eliquis. The remaining pivotal program, LILAC-TIMI 76 in atrial fibrillation patients unsuitable for oral anticoagulants, is still recruiting with estimated completion in December 2027. For a mega-cap diversified pharma, abelacimab is a modest pipeline asset with no near-term binary catalyst.
How It Works
Abelacimab is a monoclonal antibody (a lab-made protein that mimics the immune system) that blocks Factor XI, a protein in the blood that helps form clots. Unlike standard blood thinners that interfere with multiple clotting pathways and raise bleeding risk, abelacimab targets only Factor XI, the hope is it can prevent dangerous clots (strokes, pulmonary embolisms) while leaving normal wound-healing largely intact, causing less bleeding.
Trial Status
Two Phase 3 cancer-associated thrombosis trials (ASTER vs apixaban/Eliquis, and a dalteparin comparison) were terminated in early 2026 after a data review showed abelacimab failed to beat Eliquis. The remaining Phase 3 LILAC-TIMI 76 trial (abelacimab vs placebo in ~1,900-2,500 high-risk AF patients unsuitable for oral anticoagulation) is still actively recruiting across 789 sites globally, with estimated primary completion in December 2027. Additional AZALEA-TIMI 71 analyses were presented at ESC Congress 2026.
The Two-Sided Case
Upcoming Catalysts
- LILAC-TIMI 76 Phase 3 topline readout, estimated primary completion December 2027 (no firm date set)
- Any potential interim analysis or regulatory guidance from FDA/EMA on the AF program
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report